Liver, Gallbladder, and Biliary Tract Cancers

Liver, Gallbladder, and Biliary Tract Cancers

Hepatocellular carcinoma patients with baseline alpha-fetoprotein (AFP) levels greater than 400 ng/mL may derive greater benefit from second-line ramucirumab.

In a phase III trial, erlotinib performed no better than placebo when added to sorafenib in treatment-naive patients with advanced hepatocellular carcinoma.

The addition of cediranib to treatment with cisplatin/gemcitabine did not improve progression-free survival in patients with advanced biliary tract cancer, according to the results of the phase II ABC-03 trial.

Treatment with sorafenib after curative resection or ablation of hepatocellular carcinoma did not improve recurrence-free survival compared with placebo, according to the results of the phase III STORM trial.

A meta-analysis of over 15,000 patients with liver cirrhosis who were diagnosed with hepatocellular carcinoma demonstrates the benefit of screening these patients for liver tumors.

A 65-year-old woman with rheumatoid arthritis and autoimmune hepatitis presented to clinic for evaluation of a liver mass. Six months prior to presentation, workup was initiated for elevated liver enzyme levels.

An observational study has found that patients with chronic liver disease (CLD) who used aspirin or another NSAID had a reduced risk of developing hepatocellular carcinoma and a reduced risk of dying from CLD.


Subscribe to Liver, Gallbladder, and Biliary Tract Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.